Business Wire

CA-XPRIZE

Share
XPRIZE Responds to COVID-19 by Uniting a Global Alliance of Innovators to Find Unconventional Solutions to Pandemic Threats

XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, reveals the XPRIZE Pandemic Alliance, a global coalition that combines the power of collaboration, competition, shared innovation and radical thinking to accelerate solutions that can be applied to COVID-19 and future pandemics.

The XPRIZE Pandemic Alliance launched to address the immediate needs of the COVID-19 crisis by expanding visibility into solutions underway. This launch comes with an open call to arms to the world’s innovators, clinicians, researchers, data scientists, institutions, and experts to join the Alliance and share existing work and resources using covid19.xprize.org . This website will allow the global community to:

  • Participate in the latest breakthroughs, research and solutions in development;
  • Make asks of what they need and allow XPRIZE, the Alliance members and their vast network of supporters and partners to offer their resources to help enable and accelerate innovators to reach their goals faster.

In the immediate term, the Alliance will focus on areas such as accelerating solutions for remote care, provisioning personal protective equipment to the front lines, increasing access to testing, and improving food and medicine security for vulnerable populations, among others.

As part of this Alliance, researchers and scientists are invited to share and access data through the XPRIZE Data Collaborative, a unique platform for researchers and innovators to collaborate, share and learn from data in a broad spectrum of fields in their search for solutions. This trove of data aims to unlock new approaches to fighting pandemics and will serve as the backbone to the collective effort that will prepare us for additional pandemic spikes like COVID-19, or other viral threats.

As part of the XPRIZE Data Collaborative, our launch partner, Anthem, is taking the lead by providing vetted partners with access to one of the largest certified deidentified data set including years of longitudinal data for prior viral outbreaks (e.g., swine flu, avian flu, influenza).

XPRIZE will also host and launch a series of rapid data challenges in support of the Alliance’s initiatives, which may include developing an early warning system for future pandemics, predictive models for public health resource allocation, more efficient and affordable diagnostics, treatments and cures that can be rapidly reproduced, or others based on insights drawn from the collaborators.

Other notable global partners that have already agreed to join the Alliance include United States Department of Veterans Affairs, Ending Pandemics, Intel, Illumina, IEEE Standards Association, MIT Solve, C2 International, Cloudbreak Health, the Foundation Botnar, McGill University, Nvidia, the Patrick J. McGovern Foundation, PPE Coalition, and UCSD. XPRIZE is actively calling for more partners and members to join the Alliance.

“There are few times in recent history when one pandemic has affected so many people, but with all of us focused on one problem, it means impact and solutions will only be accelerated, and we’re excited to work with Anthem to amplify the potential of this platform in quickly enabling global talent to join the fight,” said XPRIZE CEO Anousheh Ansari . “At XPRIZE, we believe radical breakthroughs can come from anyone, anywhere, and our response to COVID-19 will help provide solutions when humanity’s most vulnerable need it most.”

“In this time of crisis, we see an opportunity to come together as a community via the powerful XPRIZE platform to address the most acute needs in the system today and to accelerate new solutions: from protecting our healthcare workers at the front lines and proactively taking care of the high risk populations to developing new approaches to diagnostics, therapy and vaccines,” said Rajeev Ronanki, Chief Digital Officer at Anthem.

“COVID-19 is not the first, nor the last pandemic humanity will face, and future pandemics could be far worse,” said XPRIZE Founder and Executive Chairman Peter H. Diamandis , MD. “For 25 years, XPRIZE has focused on solving global grand challenges, crowdsourcing solutions. The XPRIZE does this by inspiring innovators around the world to use exponential technologies to address problems in unbelievably short timeframes. The XPRIZE Pandemic Alliance will leverage data and human collaboration like never before to facilitate technological breakthroughs for the benefit of humankind.”

For more information, visit covid19.xprize.org .

Additional Quotes from XPRIZE Pandemic Alliance Partners:

“Technology can play a role in helping us to address the world’s largest challenges,” said Stacey Shulman, Chief Innovation Officer and VP, IOT Group, Intel. “Intel is partnering with XPRIZE to enable the larger community to find creative and impactful solutions for this global pandemic.”

“Never before have we had both the technology and collective will to develop a proactive global network for real time assessment and monitoring of infectious epidemics,” said Dr. Phil Febbo, Senior Vice President and Chief Medical Officer, Illumina. “We are pleased to be participating and helping to ensure that laboratories using our sequencers worldwide can integrate into a global community committed to preventing pandemics.”

“In response to the ongoing threat of COVID-19, Solve is focused on finding and supporting innovative solutions that address global health preparedness, early detection, and rapid response,” said Alex Amouyel, Executive Director at MIT Solve. “Better data sharing and analysis is one area that is critical in the effort to slow and track the spread of COVID-19 and future disease outbreaks—and Solve is pleased to join the XPRIZE Global Pandemic Data Alliance in that endeavor.”

"We are finding solutions and new innovations guided by lived experience, empathy, and a love of humanity and coming from unexpected and underexplored sources—makers/tinkerers who are also frontline health workers, student inventors, data scientists driven by social purpose," said Vilas Dhar, Trustee of the Patrick J. McGovern Foundation. "This Alliance creates a platform to engage those actors and many more in a shared quest to alleviate suffering and create a new paradigm for pandemic response."

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to accelerate the development of technological breakthroughs that benefit humanity. Active competitions include the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE, the $20 Million NRG COSIA Carbon XPRIZE, and the $10 Million Rainforest XPRIZE. For more information, visit xprize.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye